Ad
related to: ocul
Search results
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Given Consensus Recommendation of “Moderate Buy” by...
ETF DAILY NEWS· 1 day agoOcular Therapeutix, Inc. (NASDAQ:OCUL – Get Free Report) has been given an average recommendation of “Moderate Buy” by the six research firms that are covering the firm, Marketbeat ...
Ocular Therapeutix (NASDAQ:OCUL) PT Lowered to $14.00 at HC Wainwright
ETF DAILY NEWS· 1 day agoOcular Therapeutix (NASDAQ:OCUL – Free Report) had its price objective trimmed by HC Wainwright from $16.00 to $14.00 in a research report released on Wednesday morning, Benzinga ...
OCUL Shares Experience Decline in Value – Knox Daily
Knox Daily· 2 days agoAs published in their initiating research note from BofA Securities on February 09, 2024, Ocular Therapeutix Inc [OCUL] has been a Buy and the price target has been revised ...
Ocular Therapeutix: Q1 Earnings Snapshot
The Woonsocket Call· 4 days agoBEDFORD, Mass. (AP) — BEDFORD, Mass. (AP) — Ocular Therapeutix Inc. (OCUL) on Tuesday reported a loss of $64.8 million in its first quarter.
Ocular Therapeutix stock target cut, Buy rating kept By Investing.com
Investing.com· 4 days agoOn Wednesday, H.C. Wainwright adjusted its price target on shares of Ocular Therapeutix (NASDAQ:OCUL...
EyePoint Pharmaceuticals’ stock plunges as eye treatment fails to meet trial goal
Market Watch· 6 days agodropped nearly 30% in premarket trading Monday after the company said its experimental...
Ocular Therapeutix Inc Reports First Quarter 2024 Earnings
GuruFocus.com via Yahoo Finance· 4 days agoFinancial Outlook: Cash reserves expected to support operations into 2028, providing stability for...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 5 days agoOcular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization ...
12 Health Care Stocks Moving In Monday's Pre-Market Session - Acutus Medical (NASDAQ:AFIB), Addex...
Benzinga· 6 days agoThe market value of their outstanding shares is at $685.9 million. NeuBase Therapeutics NBSE shares fell 16.47% to $0.34. The company's market cap stands at $1.2 million. Ocular Therapeutix ...
